Topic · 3 reports
Controlled Substances Act
RegulationWatch reporting on controlled substances act matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- Controlled Substances Act
CVS agrees to pay $315 million to settle federal opioid dispensing case
The Justice Department announced that CVS Pharmacy will pay $315 million to resolve Controlled Substances Act and False Claims Act allegations that it filled unlawful opioid prescriptions and billed federal programs for them. CVS admitted no liability and signed a compliance agreement with the DEA.
- Controlled Substances Act
The Justice Department says CVS filled unlawful opioid prescriptions for over a decade. Nearly two years on, nothing is decided.
The complaint is an allegation, and CVS denies it. It describes a company whose own pharmacists and data raised the alarm.
- Controlled Substances Act
McKesson reported 16 suspicious orders out of 1.6 million. The penalty was $150 million.
It was the company's second settlement for the same failure. The first, in 2008, had required it to build a monitoring system.
